

UNITED STATES INTERNATIONAL TRADE COMMISSION  
Washington, DC 20436

**MEMORANDUM ON PROPOSED TARIFF LEGISLATION  
of the 110<sup>th</sup> Congress<sup>1</sup>**

[Date approved: May 16, 2008]<sup>2</sup>

**Bill No. and sponsor:** H.R. 4677 (Mr. Christopher S. Murphy of Connecticut and Mr. Christopher Shays of Connecticut).

**Proponent name,<sup>3</sup> location:** Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.

**Other bills on product (110<sup>th</sup> Congress only):** None.

**Nature of bill:** Temporary duty suspension through December 31, 2011.

**Retroactive effect:** None.

**Suggested article description(s) for enactment (including appropriate HTS subheading(s)):**

2-Cyclopropylaminonicotinic acid (CAS No. 639807-18-4) (provided for in subheading 2933.39.61).

**Check one:**     \_\_\_ Same as that in bill as introduced.  
                  X Different from that in bill as introduced (see Technical comments section).

**Product information, including uses/applications and source(s) of imports:**

The subject product is a synthetic organic chemical that is used as an intermediate in the production of a drug that treats HIV. The proponent imports this chemical from France.

**Estimated effect on customs revenue:**

<b>HTS subheading: <u>2933.39.61</u></b>					
<del> </del>	2009	2010	2011	2012	2013
Col. 1-General rate of duty	6.5%	6.5%	6.5%	6.5%	6.5%
Estimated value <i>dutiable</i> imports	\$1,200,000	\$1,200,000	\$1,200,000	\$1,200,000	\$1,200,000
Customs revenue loss	\$78,000	\$78,000	\$78,000	\$78,000	\$78,000

Source of estimated dutiable import data: U.S. industry estimates.

**Contacts with domestic firms/organizations (including the proponent):**

<sup>1</sup> Industry analyst preparing report: Philip Stone (202-205-3424); Tariff Affairs contact: David Michels (202-205-3440).

<sup>2</sup> Access to an electronic copy of this memorandum is available at [http://www.usitc.gov/tata/hts/other/rel\\_doc/bill\\_reports/](http://www.usitc.gov/tata/hts/other/rel_doc/bill_reports/).

<sup>3</sup> The sponsor/proponent did not identify any additional beneficiaries of this bill.

Name of firm/organization	Date contacted	Claim US makes same or competing product(s)?	Submission attached?	Opposition noted?
		(Yes/No)		
Boehringer Ingelheim Pharmaceuticals (Proponent) Henry Menn, Email: HMenn@brownrudnick.com	03/19/2008	No	No	No
Abbott Laboratories Claude Burcky, Fax: 202-783-6631	03/19/2008	No	No	No
Bayer Corp. Karen Niedermeyer, Fax: 412-777-4740 Julie Van Egmund, Fax: 202-737-8909	03/19/2008	No	No	No
Bristol Myers Squibb Company David Warr, Fax: 202-783-2308	03/19/2008	No	No	No
Clariant Corporation Andrew Zamoyski, Fax: 202-248-9043	03/19/2008	No	No	No
DuPont Helen McMahon, Fax: 302-355-2994	03/19/2008	No	No	No
Eli Lilly Kathy Karol, Fax: 202-624-9460	03/19/2008	No	No	No
Endo Pharmaceuticals Albert McCorwick, Fax: 484-840-4277	03/19/2008	No	No	No
Gilead Sciences Cheryl Myriad, Fax: 650-522-5853	03/19/2008	No	No	No
GlaxoSmithKline William Schuyler, Fax: 202-715-1001	03/19/2008	No	No	No
Interferon Sciences, Inc. Samuel Ronel, Fax: 732-249-6895	03/19/2008	No	No	No
Lonza Inc. Cheryl Prescott, Fax: 201-696-3558	03/19/2008	No	No	No
Merck Thomas Bombelles, Fax: 202-638-3670	03/19/2008	No	No	No
Monsanto Grant Erdel, Fax: 202-789-1867	03/19/2008	No	No	No
Niche Pharmaceuticals Steve Brandon, Fax: 817-491-3533	03/19/2008	No	No	No
Novartis Tracy Haller, Fax: 202-628-4763	03/19/2008	No	No	No

Name of firm/organization	Date contacted	Claim US makes same or competing product(s)?	Submission attached?	Opposition noted?
Pfizer Katherine Bennett, Fax: 202-347-2044	03/19/2008	No	No	No
Procter and Gamble Jim McCarthy, Fax: 202-393-4606	03/19/2008	No	No	No
Schering-Plough Rob Lively, Fax: 202-463-8809	03/19/2008	No	No	No
Watson Sarah Sweet, Fax: 951-270-1429	03/19/2008	No	No	No

**Technical comments:<sup>4</sup>**

The Commission staff suggests the article description on page 1 of this report be used because it contains the correct chemical name.

---

<sup>4</sup> The Commission may express an opinion on the HTS classification of a product to facilitate consideration of the bill. However, by law, only the U.S. Customs Service is authorized to issue a binding ruling on this matter. The Commission believes that the U.S. Customs Service should be consulted prior to enactment of the bill.

110TH CONGRESS  
1ST SESSION

# H. R. 4677

To suspend temporarily the duty on Cyclopropylaminonicotinic acid.

---

## IN THE HOUSE OF REPRESENTATIVES

DECEMBER 13, 2007

Mr. MURPHY of Connecticut (for himself and Mr. SHAYS) introduced the following bill; which was referred to the Committee on Ways and Means

---

## A BILL

To suspend temporarily the duty on  
Cyclopropylaminonicotinic acid.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. CYCLOPROPYLAMINONICOTINIC ACID.**

4 (a) IN GENERAL.—Subchapter II of chapter 99 of  
5 the Harmonized Tariff Schedule of the United States is  
6 amended by inserting in numerical sequence the following  
7 new heading:

“	9902.01.00	Cyclopropylaminonicotinic acid (2-CAN) (CAS No. 639807–18–4) (provided for in subheading 2933.39.61) ..	Free	No change	No change	On or before 12/31/2011	”.
---	------------	---	------	-----------	-----------	-------------------------	----

1       (b) EFFECTIVE DATE.—The amendment made by  
2 subsection (a) applies to articles entered, or withdrawn  
3 from warehouse for consumption, on or after the 15th day  
4 after the date of the enactment of this Act.

○